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THE C3H/HeJ strain of mice obtained
from the Jackson Laboratory (Bar Harbor,
Maine, U.S.A.) shows a high incidence of
spontaneous mammary cancer (Green,
1966). Bacillus Calmette Guerin (BCG)
is an effective immunopotentiator and
has been used as an adjuvant to control
neoplastic growth in both experimental
animals and humans. In all probability, it
exerts this action by enhancing the macro-
phage response to foreign antigen (Hersh,
Gutterman and Mavleget, 1977).
A multitude of papers reviewed by
Bardawil and Troy (1959) attests to the
various effects produced in experimental
animals by immunization with hetero-
logous antisera to placental homogenates.
The use of placental tissue alone for
immunization has also been examined
(Jones, Ing and Kaye, 1972). The effect of
a combined vaccine containing auto-
genous placenta and BCG on the incidence
of autochthonous mammary cancer in a
highly susceptible animal has not hitherto
been adequately investigated and is the
subject of this study.
Tumour cells possess at least 2 antigens
at the cell surface which elicit cellular
immune reaction: foetal antigen and
tumour-specific transplantation antigen
(TSTA). The current belief is that these 2
antigens may not be distinct entities
but are both the expression of normal
cellular components present during normal
embryonic development (Coggen and
Anderson, 1972).
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C3H/HeJ mice were mate(l at the
Animal Room of the Department. At the
birth of a litter, the placenta was salvaged
and the mother was allowe(l to inurse her
litter. The placenta was macerated into
fragments containing from 10 to 300 cells.
The cell suspension was washed in normal
saline and centrifuged. The pellet, was
then stored at -400C.
When the placenta-donor mice reached
21 days of age, they were weaned and
divided in 3 groups. Each group con-
tained 30 mice and the sibs from individual
litters were placed in each group. (Group A
served as control. Group B was given a
single s.c. injection of BCG containing
01 ml of the University of Montreal
standard live BCG-diluent complex. Group
C was given a single s.c. injection of the
combined vaccine. This vaccine was in-
dividually prepared for each animal, and
contained the total prepared cellular frag-
ments of single placenta from the donor,
mixed with the same quantity of BCG
as in Group B. The mice were exami-
ned every third day to detect and recordl
the presence and development of ma-
mmary-glandmalignancies. The age of the
animal at the time of the first discer-
nible appearance of a malignant ma-
mmary tutmour and at the time of its
death was recor(led. Only female
breeding mice were studied. Tumour-s
other than malignant mnamnmary grow-
ths were excluded from this study.
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TABLE.-Number of Mice with Cancer (30 per group)
Age of mice (months)
Group
Control (A)
BCG vaccine (B)
BCG-placenta vaccine (C)
healthy mice that developed benign
parotid tumours. Group C contained 2
healthy mice with benign parotid tumours
and a third animal which developed a
benign parotid tumour but was already
bearing a mammary-gland malignancy.
This animal was included in the statistical
analysis of Group C. The nature of the
tumorous growths was determined cyto-
logically.
The incidences ofautochthonous tumour
in the 3 groups are shown in the Table.
The control group followed precisely the
tumour incidence predicted by the Jackson
Laboratory, Group B, which contained
BCG alone, showed a delay of one month
in tumour development, with the inci-
dence at 14 months being 6% less than in
Group A. The group that was given the
combined vaccine (C) showed a delay of 5
months before tumours were evident and
the incidence at 14 months was 530 less
than in the control group. Logrank values
using the Peto and Pike derivatives
give x2 for Group A vs Group B of 0X4624
with the probability of 0 5. This suggests
that the BCG vaccine alone has no
statistically acceptable effect on the inci-
dence of malignant tumours. Logrank
values for Group A vs Group C give a
x2 of 7 8867 (P<001). Consequently,
it can be assumed that the combined
vaccine has a highly significant effect in
reducing the incidence of malignant mam-
mary tumours. In addition, the interval
from the initial detection of a malignancy
to the death of the animal varied in the 3
groups. On average, Group B mice
survived 20% longer with the tumour
than did the cancerous mice in Group A,
whereas the mice in Group C survived
60% longer with the tumour than did
those in Group A.
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Placental tissue was used on the assump-
tion that the cells shared sufficient
embryonic antigen with the cancer cells to
elicit an immune response when these
antigens were administered to an immuno-
logically tolerant mature animal. Tal and
Halperin (1970) reported the presence of a
placental antigen in pregnant serum and
in the serum of a wide variety of cancer
patients. The growth hormone of the
placenta, placental lactogen or chorionic
somatomammotrophin was found in 9%
of cancer patients with nontrophoblastic
cancer (Weintraub and Rosen, 1971). In
addition, chorionic gonadotrophin pro-
duction also occurs in a variety oftumours
(Rosen et al., 1968). Finally, cancers
produce a factor which stimulates the
host to provide the blood supply for the
neoplastic tissue. This tumour angiogenesis
factor (TAF) appears to be crucial to
the growth of many tumours, and is
also found in the placenta (Folkman,
1972).
Theoretically, there are a number of
ways in which the combined placenta-
BCG vaccine could reduce the incidence
ofmalignancy. The vaccine could induce a
heightened state of immunity against
antigens common to both placental cells
and cancerous cells. If this shared antigen
is present on the surface membrane, a
cell-mediated immune response may
account for the reduced incidence. If,
however, the common antigen is a cell-
mediated extracellular agent such as TAF,
a humoral antibody is implicated. In
either case the vaccine functions prophy-
lactically in producing an immunity
against the future development of cancer
cells exhibiting antigens that it shares
with the placenta.
It is also possible that the placenta
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contains a maternally derived oncogenic
virus or viruses. The placenta vaccine is
then producing immunity against a onco-
genic virus that the animal may be
destined to encounter during adult life.
It is difficult to place a milk-born Bittner-
type virus in this category since all the
mice have already been exposed to the
milk for 3 weeks before receiving any
vaccine.
Finally, the vaccine may reduce the
sensitivity of breast tissue to the carcino-
genic action ofendogenousbreast-stimulat-
ing hormones.
The enormous advantage that term
placenta provides in promoting immunity
against malignancy is that this is the only
tissue which becomes obsolete at the
moment of every mammal's birth and
consequently is dispensible.
We are grateful to Dr Kurt Sittmann for his
assistance. This study was supported by a grant
from the Medical Research Council of Canada
(MA-2169).
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